DKK2 mediates osteolysis, invasiveness, and metastatic spread in ewing sarcoma

Cancer Research

Volumn 73, Issue 2, 2013, Pages 967-977

  Hauer, Kristina ^a   Calzada Wack, Julia ^d   Steiger, Katja ^d   Grunewald, Thomas G P ^a   Baumhoer, Daniel ^e   Plehm, Stephanie ^a   Buch, Thorsten ^b   Da Costa, Olivia Prazeres ^b   Esposito, Irene ^c,d   Burdach, Stefan ^a   Richter, Günther H S ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Institute for Medical Microbiology Immunology and Hygiene   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DKK2 PROTEIN; INTERSTITIAL COLLAGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE TISSUE; CANCER GROWTH; CANCER INFILTRATION; CANCER INVASION; CARTILAGE CELL; CELL DIFFERENTIATION; CELL HOMING; CONTROLLED STUDY; CORRELATION ANALYSIS; CXCR4 GENE; DKK2 GENE; EWING SARCOMA; GENE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; HYPOXIA INDUCIBLE FACTOR 1ALPHA GENE; IL6 GENE; IN VITRO STUDY; IN VIVO STUDY; JAG1 GENE; METASTASIS; MOUSE; NERVE CELL; NONHUMAN; OSTEOCYTE; OSTEOLYSIS; PRIORITY JOURNAL; PTHRP GENE; RNA INTERFERENCE; RUNX2 GENE; SARCOMA CELL; TRANSFORMING GROWTH FACTOR BETA1 GENE; TUMOR XENOGRAFT; VEGF GENE;

ANIMALS; BONE NEOPLASMS; CELL DIFFERENTIATION; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; NEURONS; OSTEOLYSIS; SARCOMA, EWING; TRANSPLANTATION, HETEROLOGOUS; UP-REGULATION;

EID: 84872537847     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-1492     Document Type: Article

References (45)

1. Lessnick SL, Ladanyi M. Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets. Annu Rev Pathol 2012; 7: 145-59.
2. Mackintosh C, Madoz-Gurpide J, Ordoñez JL, Osuna D, Herrero- Martín D. The molecular pathogenesis of Ewing's sarcoma. Cancer Biol Ther 2010;9: 655-67.
3. Ewing J. Classics in oncology. Diffuse endothelioma of bone. James Ewing. Proceedings of the New York Pathological Society, 1921. CA Cancer J Clin 1972;22: 95-8.
4. Schmidt D, Harms D, Burdach S. Malignant peripheral neuroectodermal tumours of childhood and adolescence. Virchows Arch A Pathol Anat Histopathol 1985;406: 351-65.
5. Burdach S, Jürgens H. High-dose chemoradiotherapy (HDC) in the Ewing family of tumors (EFT). Crit Rev Oncol Hematol 2002;41: 169-89.
6. Burdach S, Thiel U, Schöniger M, Haase R, Wawer A, Nathrath M, et al. Total body MRI-governed involved compartment irradiation combined with high-dose chemotherapy and stem cell rescue improves longterm survival in Ewing tumor patients with multiple primary bone metastases. Bone Marrow Transplant 2010;45: 483-9.
7. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12: 6243s-9s.
8. Staege MS, Hutter C, Neumann I, Foja S, Hattenhorst UE, Hansen G, et al. DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets. Cancer Res 2004;64: 8213-21.
9. Katoh M, Katoh M. WNT antagonist, DKK2, is a Notch signaling target in intestinal stem cells: augmentation of a negative regulation system for canonical WNT signaling pathway by the Notch-DKK2 signaling loop in primates. Int J Mol Med 2007;19: 197-201.
10. Brott BK, Sokol SY. Regulation of Wnt/LRP signaling by distinct domains of Dickkopf proteins. Mol Cell Biol 2002;22: 6100-10.
11. Mao B, Niehrs C. Kremen2 modulates Dickkopf2 activity during Wnt/ LRP6 signaling. Gene 2003;302: 179-83.
12. Li L, Mao J, Sun L, Liu W, Wu D. Second cysteine-rich domain of Dickkopf-2 activates canonical Wnt signaling pathway via LRP-6 independently of dishevelled. J Biol Chem 2002;277: 5977-81.
13. Uren A, Wolf V, Sun Y-F, Azari A, Rubin JS, Toretsky JA. Wnt/Frizzled signaling in Ewing sarcoma. Pediatr Blood Cancer 2004;43: 243-9.
14. Fujita K, Janz S. Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. Mol Cancer 2007;6: 71.
15. Tian E, Zhan F, Walker R, Rasmussen E,MaY, Barlogie B, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349: 2483-94.
16. Li X, Liu P, Liu W, Maye P, Zhang J, Zhang Y, et al. Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation. Nat Genet 2005;37: 945-52.
17. Richter GHS, Plehm S, Fasan A,Rössler S, Unland R, Bennani-Baiti IM, et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci U S A 2009;106: 5324-9.
18. Grunewald TGP, Diebold I, Esposito I, Plehm S, Hauer K, Thiel U, et al. STEAP1 is associated with the invasive and oxidative stress phenotype of Ewing tumors. Mol Cancer Res 2012;10: 52-65.
19. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102: 15545-50.
20. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144: 646-74.
21. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990;61: 1303-13.
22. Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996;271: 509-12.
23. Roland CL, Harken AH, Sarr MG, Barnett CC Jr. ICAM-1 expression determines malignant potential of cancer. Surgery 2007;141: 705-7.
24. Lynch CC, Hikosaka A, Acuff HB, Martin MD, Kawai N, Singh RK, et al. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 2005;7: 485-96.
25. Lu X, Wang Q, Hu G, Van Poznak C, Fleisher M, Reiss M, et al. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev 2009; 23: 1882-94.
26. Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer 2011;11: 411-25.
27. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000;25: 25-9.
28. Reeves SA, Helman LJ, Allison A, Israel MA. Molecular cloning and primary structure of human glial fibrillary acidic protein. Proc Natl Acad Sci U S A 1989;86: 5178-82.
29. Benowitz LI, Routtenberg A. GAP-43: an intrinsic determinant of neuronal development and plasticity. Trends Neurosci 1997;20: 84-91.
30. Min J-K, Park H, Choi H-J, KimY, Pyun B-J, Agrawal V, et al. The WNT antagonist Dickkopf2 promotes angiogenesis in rodent and human endothelial cells. J Clin Invest 2011;121: 1882-93.
31. Miyagawa Y, Okita H, Itagaki M, Toyoda M, Katagiri YU, Fujimoto J, et al. EWS/ETS regulates the expression of the Dickkopf family in Ewing family tumor cells. PLoS One 2009;4:e4634.
32. Navarro D, Agra N, Pesta~na A, Alonso J, Gonzalez-Sancho JM. The EWS/FLI1 oncogenic protein inhibits expression of the Wnt inhibitor DICKKOPF-1 gene and antagonizes beta-catenin/TCF-mediated transcription. Carcinogenesis 2010;31: 394-401.
33. Kang H-G, Jenabi JM, Zhang J, Keshelava N, Shimada H, May WA, et al. E-cadherin cell-cell adhesion in Ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res 2007;67: 3094-105.
34. Park YS, Huh JW, Lee JH, Kim HR. shRNA against CD44 inhibits cell proliferation, invasion and migration, and promotes apoptosis of colon carcinoma cells. Oncol Rep 2012;27: 339-46.
35. Bäuerle T, Adwan H, Kiessling F, Hilbig H, Armbruster FP, Berger MR. Characterization of a rat model with site-specific bone metastasis induced by MDA-MB-231 breast cancer cells and its application to the effects of an antibody against bone sialoprotein. Int J Cancer 2005;115: 177-86.
36. LauWM, Weber KL, Doucet M, Chou Y-T, Brady K, Kowalski J, et al. Identification of prospective factors promoting osteotropism in breast cancer: a potential role for CITED2. Int J Cancer 2010; 126: 876-84.
37. Son J, Lee J-H, Kim H-N, Ha H, Lee ZH. cAMP-response-elementbinding protein positively regulates breast cancer metastasis and subsequent bone destruction. Biochem Biophys Res Commun 2010; 398: 309-14.
38. De S, Chen J, Narizhneva NV, Heston W, Brainard J, Sage EH, et al. Molecular pathway for cancer metastasis to bone. J Biol Chem 2003;278: 39044-50.
39. Bennani-Baiti IM, Cooper A, Lawlor ER, Kauer M, Ban J, Aryee DNT, et al. Intercohort gene expression co-analysis reveals chemokine receptors as prognostic indicators in Ewing's sarcoma. Clin Cancer Res 2010;16: 3769-78.
40. Li X, McGee-Lawrence ME, Decker M, Westendorf JJ. The Ewing's sarcoma fusion protein, EWS-FLI, binds Runx2 and blocks osteoblast differentiation. J Cell Biochem 2010;111: 933-43.
41. Sugawara M, Kato N, Tsuchiya T, Motoyama T. RUNX2 expression in developing human bones and various bone tumors. Pathol Int 2011; 61: 565-71.
42. Sethi N, Dai X, Winter CG, Kang Y. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 2011;19: 192-205.
43. Hoang BH, Kubo T, Healey JH, Yang R, Nathan SS, Kolb EA, et al. Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res 2004;64: 2734-9.
44. Bu G, Lu W, Liu C-C, Selander K, Yoneda T, Hall C, et al. Breast cancerderived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases. Int J Cancer 2008;123: 1034-42.
45. Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 2005;65: 7554-60.